The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer.

Viruses
Scott D HallerKarim Essani

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the fifth leading cause of cancer-related death in Western countries. The incidence of PDAC has increased over the last 40 years and is projected to be the second leading cause of cancer death by 2030. Despite aggressive treatment regimens, prognosis for patients diagnosed with PDAC is very poor; PDAC has the lowest 5-year survival rate for any form of cancer in the United States (US). PDAC is very rarely detected in early stages when surgical resection can be performed. Only 20% of cases are suitable for surgical resection; this remains the only curative treatment when combined with adjuvant chemotherapy. Treatment regimens excluding surgical intervention such as chemotherapeutic treatments are associated with adverse effects and genetherapy strategies also struggle with lack of specificity and/or efficacy. The lack of effective treatments for this disease highlights the necessity for innovation in treatment options for patients diagnosed with early- to late-phase PDAC and immuno-oncolytic viruses (OVs) have been of particular interest since 2006 when the first oncolytic virus was approved as a therapy for nasopharyngeal cancers in China. Interest resurged in 2015 when T-Vec, an oncol...Continue Reading

References

Mar 27, 2007·Cancer Letters·Markus J V Vähä-KoskelaAri E Hinkkanen
Jun 7, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Svend O FreytagJae Ho Kim
Mar 12, 2008·HPB : the Official Journal of the International Hepato Pancreato Biliary Association·D J GoumaT M Van Gulik
Jan 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Assia L AngelovaZahari Raykov
Oct 6, 2010·Advances in Surgery·Ralph H HrubanAlison P Klein
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
May 31, 2011·Lancet·Audrey VincentMichael Goggins
Jul 12, 2012·Nature Biotechnology·Stephen J RussellJohn C Bell
May 1, 2013·Nature Reviews. Clinical Oncology·Jens WernerMarkus W Büchler
Oct 18, 2013·The New England Journal of Medicine·Daniel D Von HoffMarkus F Renschler
Jan 7, 2014·Trends in Biochemical Sciences·Kirsten L BryantChanning J Der
Mar 19, 2014·Cell Host & Microbe·John Bell, Grant McFadden
Jul 6, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nicola R HardwickVincent Chung
Jul 6, 2014·Nature Reviews. Cancer·Brian D LichtyJohn C Bell
Sep 11, 2014·The New England Journal of Medicine·David P RyanNabeel Bardeesy
Nov 12, 2014·World Journal of Gastroenterology : WJG·Kentaro SudoTaketo Yamaguchi
Nov 26, 2014·Human Gene Therapy·Marion GayralPierre Cordelier
Mar 22, 2015·Cancer Immunology, Immunotherapy : CII·Laura K AguilarMark Bloomston
May 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert H I AndtbackaRobert S Coffin
Sep 2, 2015·Nature Reviews. Drug Discovery·Howard L KaufmanAndrew Zloza
Nov 26, 2015·Immunotherapy·Chadwan Al YaghchiYaohe Wang
Jan 23, 2016·Biochimica Et Biophysica Acta·Marco FalascaIlaria Casari
Apr 5, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Anne M NoonanTanios S Bekaii-Saab
May 21, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Stephanie Downs-CannerDavid L Bartlett
Nov 15, 2016·Future Oncology·Maria C PrevidiChiara Braconi
Feb 28, 2017·International Journal of Cancer. Journal International Du Cancer·Bin ZhouHan-Xiang Zhan
Apr 14, 2017·Journal of Surgical Oncology·Ahmad Rahal, Benjamin Musher
Jun 8, 2017·Journal of Surgical Oncology·Rohan GuptaVincent Chung
Jun 9, 2017·International Journal of Molecular Sciences·Marie RouanetLouis Buscail
Dec 1, 2017·Current Cancer Drug Targets·Min Liang
Mar 15, 2018·Biomedicines·Raquel T YokodaMitesh J Borad
Apr 5, 2018·Oncolytic Virotherapy·Raquel YokodaMitesh J Borad
Nov 8, 2018·Biomedicines·Christopher J LaRocca, Susanne G Warner
Nov 23, 2018·BMC Medicine·Huiyun ZhuMin Li
Nov 30, 2018·World Journal of Gastroenterology : WJG·Andrew McGuiganR Stephen McCain
Mar 19, 2019·La Presse médicale·Christoph SpringfeldJohn P Neoptolemos

❮ Previous
Next ❯

Citations

Jul 10, 2021·World Journal of Gastroenterology : WJG·Michail GalanopoulosChristos Liatsos

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
transfection
genetic modification

Clinical Trials Mentioned

NCT02819843
NCT03252808
NCT02653313
NCT00669734

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Seminars in Oncology
Kimberly J HilfrankFay Kastrinos
Translational Gastroenterology and Hepatology
Lena Haeberle, Irene Esposito
© 2021 Meta ULC. All rights reserved